MediSynergics, LLC
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
Aug 2033
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 16, 2027The maintenance fee for Bicyclic antiparasitic compounds (US 10,351,552) comes due Jan 16, 2027. Unpaid by Jul 16, 2027, it lapses early.
- 1 fee due Mar 8, 2027The maintenance fee for Cycloalkyl-diamines (US 9,126,891) comes due Mar 8, 2027. Unpaid by Sep 8, 2027, it lapses early.
- 2 fees due Sep 15, 2027
Recent changes
- 1 term has ended since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 9 of 9
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,700,563 | Kappa opioid receptor compounds In force · From the USPTO record | In force | From the USPTO record | |
| US 9,346,777 | Antiprotozoal compounds In force · From the USPTO record | In force | From the USPTO record | |
| US 9,283,196 | Cycloalkyl-diamines for CNS disorders In force · From the USPTO record | In force | From the USPTO record | |
| US 9,345,673 | Anti-cancer cycloalkyl diamines In force · From the USPTO record | In force | From the USPTO record | |
| US 9,381,170 | Cycloalkyl-diamines for neurodegenerative disorders In force · From the USPTO record | In force | From the USPTO record | |
| US 9,126,891 | Cycloalkyl-diamines In force · From the USPTO record | In force | From the USPTO record | |
| US 9,284,291 | Kappa opioid receptor compounds In force · From the USPTO record | In force | From the USPTO record | |
| US 9,517,232 | Compounds for treatment of alzheimer's disease In force · From the USPTO record | In force | From the USPTO record | |
| US 10,351,552 | Bicyclic antiparasitic compounds In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 9: 4 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 no status recorded